Weakening HIV
One person's fight against an HIV infection can decrease the virus's ability to threaten its next victim, say Goepfert et al. (page 1009) . Mutations that help the virus survive in one host decrease its ability to replicate in the next.
HIV mutations that help the virus bypass the host's immune system often fall within gag. This gene is a favorite target for mutations because, for some reason, Gag epitopes that are presented by HLA B alleles create the most productive immune response. But Gag is also critical for viral replication. The infected individual doesn't benefit from replicationdampening gag mutations, as the virus still escapes from cytotoxic T cells.
Goepfert and colleagues now find, however, that the resulting decreased replication may benefit the patient's sexual partner. Their study of 114 couples found that individuals who were infected by partners with certain HLA B alleles had much lower viral levels when more than five gag mutations were present. Viral levels were lowest in newly infected individuals who did not have the same type of HLA B alleles as their partners, perhaps because the recipients' T cells efficiently targeted non-Gag epitopes of the mutated virus. At least five gag mutations were needed to reduce viral load significantly. This threshold might explain why a T cell vaccine that induces immune responses against two Gag epitopes failed in a recent trial. Better results might be gained by targeting more epitopes.
Refilling an empty niche with proliferating CD8 + T cells can cause autoimmune disease, say Tajima et al. (page 1019).
Infusion of naive T cells into an environment where there are few native T cells-such as in patients undergoing cancer therapy-spurs two kinds of proliferation. T cells activated by non-self-peptide/MHC complexes proliferate rapidly, whereas those activated by self-peptide/ MHC in the presence of cytokines such as IL-7 and IL-15 proliferate slowly. CD4
+ T cells that proliferate by these methods have previously been shown to drive the inflammation seen in several autoimmune diseases.
Tajima et al. now find a new variation in homeostatic proliferation of CD8 + T cells that also induces autoimmunity. In gut lymph nodes of T cell-deficient mice, injected CD8 + T cells proliferated rapidly in response to IL-6. This inflammatory cytokine was found at high levels in these lymph nodes, perhaps due to their proximity to the bacterium-laden gut. The mice developed a thicker gut epithelium and lost weight-signs of an autoimmune disease called colitis. T cell-injected mice treated with an IL-6-blocking antibody or with bacteriumdepleting drugs, however, remained healthy.
The proliferating T cells secreted several inflammatory cytokines, including IL-17. The IL-17 alone seemed to be responsible for the colitis, as mice injected with T cells that were unable to produce IL-17 remained healthy. If these IL-17-producing CD8 + T cells are found in patients suffering from diseases such as colitis, the anti-IL-6 antibody might be a good therapeutic option.
A trick presentation
On page 1201, Huang et al. find that an antigenpresenting protein suffers from an identity crisis: it looks like MHC class I but behaves like MHC class II.
This molecule, MR1, is recognized by a subset of gut-roving T cells. When MR1 carries the right antigen, these T cells suppress gut inflammation, but the identity of that antigen is a mystery. Because MR1 is structurally similar to MHC class I molecules, which usually pick up proteasome-processed peptides in the ER, MR1 was thought to do the same.
This notion is now disproved by Huang et al., who show that MR1-expressing cells treated with proteasome inhibitors or lacking ER peptide-loading chaperones can still activate these T cells. Instead, they found, MR1 picked up its antigens in endosomes, where MHC class II molecules get theirs.
MR1 bound to a chaperone called the invariant chain, which ferries MHC class II molecules from the ER into endosomes. There, it bound another chaperone, called DM, which loads them up with peptides. MR1-expressing cells that lacked the invariant chain were unable to activate gut T cells, whereas high levels of this protein increased their activation.
The immune-suppressing ability of MR1-activated T cells suggests that they might prevent the gut from attacking its helpful resident flora. The authors therefore speculate that the MR1 ligand might be derived from one or more of these residents.
Autoimmune colitis (top) caused by homeostatically proliferating CD8
+ T cells is resolved in mice injected with anti-IL-6 antibody (bottom). HIV levels are lower in patients infected with viruses carrying 5 HLA B-associated Gag mutations.
Dangers of restocking T cells

